Related Experiment Video
Updated: Jul 4, 2026

Murine Endoscopy for In Vivo Multimodal Imaging of Carcinogenesis and Assessment of Intestinal Wound Healing and Inflammation
Published on: August 26, 2014
Utility of Small Bowel Capsule Endoscopy and Leucine-Rich Alpha-2-Glycoprotein in Pediatric Crohn's Disease
Satoshi Ukai1, Shun Watanabe1, Ayako Furuya1
1Pediatrics, Shinshu University School of Medicine, Matsumoto, JPN.
Abstract:
Introduction Mucosal remission is a key treatment goal for Crohn's disease (CD). Small-bowel capsule endoscopy (SBCE) is a minimally invasive modality for evaluating small-bowel mucosa; however, standardized criteria for mucosal remission have not yet been established. This study aimed to investigate the correlation and comparative sensitivity of the Lewis score (LS) and Capsule Endoscopy Crohn's Disease Activity Index (CECDAI) in assessing small-bowel inflammation in pediatric Crohn's disease (CD) and to evaluate biomarkers as predictors of small bowel mucosal remission. Methods This cohort study included pediatric patients with CD at a single center in Japan. Demographics, clinical symptoms, serum C-reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), and leucine-rich alpha-2 glycoprotein (LRG) levels were evaluated. SBCE findings were scored using LS and CECDAI. Results Among 26 patients, 54 SBCEs were performed, as some patients underwent multiple examinations. Median LS and CECDAI scores were 403 and 12, respectively. LS and CECDAI showed positive correlation (ρ = 0.82, p < 0.001). LS values of 135 and 790 corresponded to CECDAI of 7.1 and 16.5, respectively. Among 32 clinical remission cases, 24 had LS ≥ 135, while 17 had CECDAI ≥ 7.1. CRP, ESR and LRG correlated with SBCE findings, with LRG showing the strongest association (ρ = 0.74, p = 0.01). LRG < 13.4 µg/mL predicted small bowel mucosal remission. Conclusions LS and CECDAI showed a strong correlation, supporting their utility in evaluating small bowel inflammation in pediatric Crohn's disease. LS may have a tendency to detect milder or subclinical inflammatory changes, although the magnitude of this difference should be interpreted cautiously. In addition, LRG < 13.4 µg/mL strongly predicted mucosal remission, and these findings, though limited by sample size, suggest that LRG combined with clinical indices could serve as a noninvasive adjunct for timing SBCE.
More Related Videos
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Endoscopic Procedures III: Video Capsule Endoscopy
Endoscopic Procedures V: ERCP
Patient...